This continued cycle of prolifer-
cells reach bone marrow niches [91]. Both human mobilized ation, self-renewal, migration and differentiation probably
HSCs and umbilical cord blood HSCs are CD47hi [91], but occurs at lower rates than haematopoiesis or intestinal cell
not as high as AML cells, including but not limited to LSC turnover, but is similarly susceptible to mutations and epige-
[91,92]. In fact, all human cancers tested upregulate CD47 netic change. It is clear from the discussion of progression to
[92-98]. Antibodies or engineered proteins that block CD47- leukaemic malignancy above that the same will apply toneu- â€” -s
SIRPa interactions lead to cancer/leukaemia phagocytosis by rogenesis, e.g. for the development of glioblastoma, and that =
macrophages in vitro, and alone or in combination with other should be testable when downstream oligolineage progenitors =
anti-tumour monoclonal antibodies of the IgG1 isotype that in neural lineages get to the point of having prospectively iso- -
binds to the prophagocytic high affinity FcR on macrophages lated intermediates from human or mouse neural stem cells. 2
lead to human tumour xenografts in immune deficient NSG A curiosity is the many cases of neurodegenerative disease S
mice to be cleared, or slowed in growth [92-97,99], and elimin- that derive from germline-inherited mutations, but do not w
ates human tumour metastases [96,100].